You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Ovarian cancer using novel nanoparticle formulations

    SBC: Kiromic BioPharma, Inc.            Topic: 102

    DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Optimized lactoferrin for treatment of intracerebral hemorrhage

    SBC: Pharmareview Corporation            Topic: NINDS

    DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Ex vivo purging strategy for treatment of multiple myeloma

    SBC: Dnatrix, Inc            Topic: NCI

    DESCRIPTION (provided by applicant): The ultimate goal of this application is to develop a novel ex vivo purging method using myxoma virus (MYXV), a rabbit-specific poxvirus, to improve the clinical outcomes in treatment of multiple myeloma (MM). MM is aclonal plasma cell malignancy that has to date resisted essentially all therapeutic strategies. Currently, the standard of care for patients wit ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a Nrf2 activator for the treatment of scleroderma

    SBC: CUREVEDA, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Screening for Novel CBS Inhibitors for Cancer Therapy

    SBC: CBS THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide (H2S) in colorectal cancer: selective upregulation of cystathionine-b-synthase (CBS) and the subsequent production of H2S in colonic cancer cells serves as a pro-survival factor by stimulating tumor cell bioenergetics, growth, proliferation, migratio ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government